Neuroxelin is a synthetic neuroprotective peptide proposed to modulate NMDA receptor activity and downregulate excessive microglial activation. It is theorized to protect neurons from excitotoxic damage while promoting synaptic plasticity. No peer-reviewed clinical trials or substantial preclinical publications exist; evidence is limited to vendor literature and preliminary in vitro data. It represents one of many novel neuropeptides marketed to the biohacking community without robust scientific validation.
Category: Cognitive / Neuroprotection. Evidence rating: D (animal/preclinical only).
Clinical status: No clinical trials. No substantial peer-reviewed publications. Vendor/manufacturer claims only.
Neuroxelin is proposed to act as a partial NMDA receptor modulator, reducing excessive glutamatergic excitotoxicity without completely blocking receptor function (preserving physiological signaling needed for learning and memory). It is also claimed to downregulate M1 microglial polarization,…
Safety considerations: No safety data from clinical trials; Unknown side effect profile; Theoretical risk of NMDA modulation-related effects (dissociation, cognitive disruption at high doses).
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
| US regulatory status | Unregulated research chemical. Not FDA-reviewed or approved. |
Related peptides: Methylene Blue.
Neuroxelin has minimal peer-reviewed evidence. The mechanisms described are plausible based on general neuropharmacology principles, but specific efficacy and safety data for this particular compound are essentially nonexistent.
Cerebrolysin has decades of clinical research with multiple randomized trials in stroke and dementia. Neuroxelin has no published clinical data. They are not comparable in terms of evidence quality.
Neuroxelin is a synthetic neuroprotective peptide proposed to modulate NMDA receptor activity and downregulate excessive microglial activation. It is theorized to protect neurons from excitotoxic damage while promoting synaptic plasticity. No peer-reviewed clinical trials or substantial preclinical publications exist; evidence is limited to vendor literature and preliminary in vitro data. It…
On the PeptideAtlas A–F scale, Neuroxelin is rated D (Preclinical Only). Mostly animal or preclinical evidence
No clinical trials. No substantial peer-reviewed publications. Vendor/manufacturer claims only.